Iptacopan is a first-in-class, oral small-molecule factor B inhibitor that targets the alternative complement pathway. It binds to complement factor B, preventing the formation of C3 convertase, which stops C3b-mediated extravascular hemolysis and downstream C5-mediated intravascular hemolysis, effectively treating diseases like paroxysmal nocturnal hemoglobinuria (PNH). The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Fabhalta and Iptacopanum. Its PubChem CID is 90467622.
Iptacopan
| CAS No | 1644670-37-0 |
|---|---|
| Molecular Formula | C25H30N2O4 |
| Molecular Weight | 422.5 g/mol |
| Synonyms | 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Iptacopan is a first-in-class, oral small-molecule factor B inhibitor that targets the alternative complement pathway.
The listed CAS number is 1644670-37-0.
The listed molecular formula is C25H30N2O4.
The listed molecular weight is 422.5 g/mol.
4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid.
The source lists Fabhalta and Iptacopanum.